Metabolic signatures and predictive biomarkers of liposomal doxorubicin-induced hypersensitivity in breast cancer: A pilot study
{{output}}
Background: Liposomal doxorubicin hypersensitivity significantly affects breast cancer patients, with widely varying incidence rates (9 % to 46 %). Despite its efficacy, this condition poses a critical barrier to treatment due to... ...
